Ascendis Pharma A Revenue Growth Rates (ASND), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Ascendis Pharma A  (NASDAQ: ASND)
 

ASND's Revenue Growth by Quarter and Year

Ascendis Pharma A's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ASND Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 278.99
3rd Quarter September 249.64
2nd Quarter June 179.25
1st Quarter March 106.32
FY 814.20

ASNDs Annual Revenue
Ascendis Pharma A's Revenue in the fiscal year 2025 $ 806.55 millions
Ascendis Pharma A's Revenue in the fiscal year 2024 $ 407.28 millions
Ascendis Pharma A's Revenue in the fiscal year 2023 $ 288.50 millions
Ascendis Pharma A's Revenue in the fiscal year 2022 $ 57.31 millions
Ascendis Pharma A's Revenue in the fiscal year 2021 $ 8.71 millions




ASND Revenue fourth quarter 2024 Y/Y Growth Comment
Ascendis Pharma A reported Revenue rise of 49.14% year on year in the fourth quarter 2024, to $ 278.99 millions, this is lower than Ascendis Pharma A's recent average Revenue surge of 137.05%.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue growth. While Ascendis Pharma A' s Revenue jump of 49.14% ranks overall at the positon no. 1063 in the fourth quarter 2024.


ASND Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December 49.14 % 26.25 % 509.79 % 321.88 %
3rd Quarter September 292.89 % 21.54 % 239.7 % 1074.81 %
2nd Quarter June 362.46 % -24.88 % 686.59 % 433.33 %
1st Quarter March 2.14 % 188.82 % 370.5 % 751.11 %
FY   106.93 % 36.57 % 434.41 % -

Financial Statements
Ascendis Pharma A's fourth quarter 2024 Revenue $ 278.99 millions ASND's Income Statement
Ascendis Pharma A's fourth quarter 2023 Revenue $ 187.07 millions Quarterly ASND's Income Statement


ASND Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December 11.76 % 194.41 % 183.44 % 57.89 %
3rd Quarter September 39.27 % 63.93 % 1.32 % 134.6 %
2nd Quarter June 68.59 % -62.76 % 43.17 % -14.36 %
1st Quarter March -43.17 % -29.75 % 48.31 % 32.99 %
FY (Year on Year)   106.93 % 36.57 % 434.41 % -


Back to ASND Growth rate Comparisons >> Back to ASND Growth rate Comparisons >>


Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #217
Overall #1063

Revenue Y/Y Growth Statistics
High Average Low
557.93 % 137.05 % -48.01 %
(Dec 31 2022)   (Dec 31 2020)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #217
Overall #1063
Revenue Y/Y Growth Statistics
High Average Low
557.93 % 137.05 % -48.01 %
(Dec 31 2022)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Ascendis Pharma A's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
53223.56 % 2079.16 % -88.46 %
(Dec 31 2018)  


ASND's IV. Quarter Q/Q Revenue Comment
Ascendis Pharma A achieved in the IV. Quarter 2024 below company average Revenue rise of 11.76% quarter on quarter, to $ 278.99 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Ascendis Pharma A's Revenue growth quarter on quarter, overall rank is 1083.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #233
Overall #1083
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #100
Healthcare Sector #233
Overall #1083
Revenue Q/Q Growth Statistics
High Average Low
53223.56 % 2079.16 % -88.46 %
(Dec 31 2018)  


ASND's IV. Quarter Q/Q Revenue Comment
Ascendis Pharma A achieved in the IV. Quarter 2024 below company average Revenue rise of 11.76% quarter on quarter, to $ 278.99 millions.

Within Major Pharmaceutical Preparations industry 99 other companies have achieved higher Revenue quarter on quarter growth. While Ascendis Pharma A's Revenue growth quarter on quarter, overall rank is 1083.


Ascendis Pharma A's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 806.55 $ 407.28 $ 288.50 $ 57.31 $ 8.71
Y / Y Revenue Growth (TTM) 98.03 % 41.17 % 403.36 % 557.93 % 11.87 %
Year on Year Revenue Growth Overall Ranking # 1063 # 0 # 1086 # 0 # 0
Seqeuential Revenue Change (TTM) 98.03 % 41.17 % 403.36 % 557.93 % 11.87 %
Seq. Revenue Growth (TTM) Overall Ranking # 1063 # 0 # 1961 # 0 # 0


Cumulative Revenue growth Comment
Although Ascendis Pharma A's Annual Revenue growth year on year were below company's average 137.05% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 98.03% year on year, from 41.17% in Dec 31 2024.

In the Healthcare sector 216 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1063.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 217
Overall # 1063

Revenue TTM Y/Y Growth Statistics
High Average Low
557.93 %
 137.05 %
-48.01 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 217
S&P 500 # 1063
Cumulative Revenue growth Comment
Although Ascendis Pharma A's Annual Revenue growth year on year were below company's average 137.05% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 98.03% year on year, from 41.17% in Dec 31 2024.

In the Healthcare sector 216 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 1063.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 86
Healthcare Sector # 217
Overall # 1063

Revenue TTM Y/Y Growth Statistics
High Average Low
557.93 %
137.05 %
-48.01 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 86
Sector # 217
S&P 500 # 1063




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ASND's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Oculis Holding Ag85.72%$ 85.722 millions
Alnylam Pharmaceuticals Inc 84.95%$ 84.945 millions
Day One Biopharmaceuticals Inc 83.92%$ 83.915 millions
Neuronetics Inc 82.17%$ 82.169 millions
Arcutis Biotherapeutics Inc 81.48%$ 81.478 millions
Aclarion Inc 80.59%$ 80.590 millions
X4 Pharmaceuticals Inc79.08%$ 79.079 millions
Intellia Therapeutics Inc 78.79%$ 78.787 millions
Envoy Medical Inc 78.57%$ 78.571 millions
Organogenesis Holdings Inc 78.13%$ 78.126 millions
Tg Therapeutics Inc 78.00%$ 78.004 millions
Eton Pharmaceuticals Inc 77.14%$ 77.140 millions
Trisalus Life Sciences Inc 76.95%$ 76.954 millions
Co diagnostics Inc 76.74%$ 76.743 millions
Ss Innovations International Inc76.54%$ 76.537 millions
Cellectis S a 75.76%$ 75.760 millions
Fennec Pharmaceuticals Inc 73.84%$ 73.842 millions
Travere Therapeutics Inc 73.41%$ 73.410 millions
Inspiremd Inc 69.30%$ 69.299 millions
Viridian Therapeutics Inc 68.06%$ 68.056 millions
Sol gel Technologies Ltd 68.04%$ 68.036 millions
Novavax inc 66.61%$ 66.615 millions
Beyond Air Inc 65.61%$ 65.605 millions
Axsome Therapeutics Inc 65.03%$ 65.030 millions
Kiniksa Pharmaceuticals International Plc64.95%$ 64.953 millions
Precision Optics Corporation Inc 62.76%$ 62.757 millions
Organigram Global Inc 62.15%$ 62.151 millions
Cardiff Oncology Inc 62.00%$ 62.000 millions
Beta Bionics Inc 61.17%$ 61.174 millions
Catheter Precision Inc 59.73%$ 59.732 millions


About Ascendis Pharma A Revenue Growth Rates (ASND), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ascendis Pharma A s (CIK 1612042).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-046590
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ascendis Pharma A s’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.